Stadalax

Quick links to important sections

Stadalax

Method of action: Laxative

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stadalax

Property Description
Active ingredient Bisacodyl
Form Enteric-coated tablet, Suppository
Pharmacological class Stimulant Laxative (Contact Laxative)
Common use Facilitating comfortable bowel emptying
Origin Synthetic (Diphenylmethane derivative)

What is Stadalax and What is its Primary Classification?

Stadalax is a proprietary, synthetic pharmaceutical preparation containing Bisacodyl as its sole active ingredient. Bisacodyl is categorized as a stimulant laxative, a class of medicine clinically recognized for promoting effective bowel action.

The drug belongs to the specific chemical family known as Diphenylmethane derivatives, a classification that confirms its origin as a manufactured compound. It is also designated a contact laxative because its function relies on direct physiological interaction with the lining of the large bowel. Stadalax is positioned for the temporary relief of difficult or incomplete bowel movements, offering an established solution for individuals seeking assistance with elimination. The compound targets the colon to stimulate peristalsis and water secretion, providing reliable relief.

Composition, Forms, and General Purpose

The medication is commonly available in multiple dosage forms tailored to different routes of administration, including the enteric-coated tablet, which is taken orally, and the rectal suppository.

The enteric-coated tablet is strategically engineered to resist stomach acids, ensuring the Bisacodyl is released only upon reaching the colon, the intended site of action, which is a distinctive formulation feature that maximizes its efficacy. Conversely, the suppository form uses a fatty or glyceride base that allows the active ingredient to act locally and quickly within the rectum. Both single-agent forms achieve the common therapeutic goal of modulating intestinal motility, which facilitates the passage of stool and ultimately restores comfortable bowel function.

Regulatory References

  1. Bisacodyl - StatPearls - NCBI Bookshelf
  2. Bisacodyl: MedlinePlus Drug Information

What side effects are possible with Stadalax?

Possible Side Effects and Safety Information

This information on side effects and safety reflects documentation from government regulatory authorities for the active ingredient, Bisacodyl (often branded as Stadalax).

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they are expected to occur:

Frequency Adverse Reaction
Common (up to 1 in 10 people) Abdominal pain, Abdominal cramps, Diarrhea
Uncommon (up to 1 in 100 people) Vomiting, Haematochezia (blood in stool), Dizziness, Abdominal discomfort
Rare (up to 1 in 1,000 people) Anaphylactic reactions, Syncope (fainting), Colitis (including ischaemic colitis), Dehydration, Hypersensitivity, Angioedema

Serious Adverse Reactions

Rare, serious reactions documented in regulatory sources include Anaphylactic reactions (severe allergic responses), Angioedema, Colitis (inflammation of the colon, including ischaemic colitis), and Syncope (fainting), often linked to a vasovagal response to severe abdominal spasms.

Safety-Related Restrictions and Cautions

  • Contraindications: The medicine must not be used if you have severe dehydration, an intestinal obstruction (ileus), acute inflammatory bowel diseases, or severe abdominal pain accompanied by nausea and vomiting.
  • Risk of Overuse: Continuous daily use or use for extended periods is restricted and can lead to significant fluid and electrolyte imbalances (e.g., low potassium), chronic diarrhea, and, in rare cases of chronic overdose, renal issues.
  • Population Note: Children under 10 years with persistent constipation should only be treated with medical guidance. The product should be used with caution in patients where dehydration would be harmful, such as the elderly or those with kidney problems.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Guidance

Information regarding Stadalax (Bisacodyl) overdose is strictly based on documented statements from government regulatory authorities.

Immediate Action Required

If you take more than the recommended dose of Stadalax, you must seek medical help immediately or go to a hospital straight away. This instruction is critical because an acute overdose can lead to significant fluid loss and electrolyte imbalance.

Documented Overdose Manifestations

Overdose manifestations vary based on exposure:

Overdose Type Primary Manifestations Documented in Labeling
Acute (Single High Dose) Watery stools (diarrhoea) and abdominal cramps.
Chronic (Prolonged Abuse) Fluid and electrolyte imbalance (e.g., hypokalaemia, dehydration), metabolic alkalosis, muscle weakness, and potentially severe outcomes such as renal tubular damage and renal calculi.

Management and Considerations

Official documents confirm that no specific antidote for Bisacodyl overdose is known. Management is supportive and focuses on preventing further absorption (e.g., gastric lavage for oral forms) and correcting the resulting fluid and electrolyte disturbances, especially potassium levels. This correction is considered especially important for older people and the young due to their increased vulnerability to dehydration.

Therapeutic Uses of Stadalax

Stadalax (Bisacodyl) is used for providing short-term symptomatic relief from occasional constipation and irregularity in adults and is relevant in key clinical contexts.

Stadalax is commonly used to help manage symptoms related to infrequent bowel movements, the physical discomfort of difficult stool passage, and the frustrating sensation of incomplete evacuation. Beyond general symptom management, it is applied in scenarios requiring additional therapeutic support, such as managing constipation secondary to opioid analgesic therapy, and is essential for achieving complete evacuation of the colon before specific diagnostic investigations or surgical procedures. This supportive assistance contributes to easing the overall symptom load during these acute or episodic changes.

Quick Fact: Relief for Straining and Infrequency


Symptomatic Relief and Clinical Use Cases

This therapeutic domain is relevant for easing symptoms that create noticeable physiological strain, helping to manage symptom clusters that may appear suddenly or fluctuate. Stadalax is considered relevant for use across conditions presenting with acute episodes and is commonly applied in clinical settings that involve temporary physiological imbalance. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability. This specialized, short-term use is essential before procedures where a clear intestinal lining is critical for supporting the successful completion of the procedure.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Stadalax (Bisacodyl)

Official regulatory information defines who can and cannot use Stadalax based on absolute contraindications, age restrictions, and physiological status. The medicine is primarily intended for short-term use and should not be taken continuously for longer than five to seven days without medical consultation.

Absolute Contraindications

Stadalax is strictly contraindicated and must not be used by patients presenting with:

  • Ileus (bowel obstruction) or other acute abdominal conditions, including acute appendicitis.
  • Severe dehydration.
  • Acute inflammatory bowel diseases.
  • Known hypersensitivity to Bisacodyl or its components.

Age-Based and Physiological Restrictions

Population Group Eligibility Status (Regulatory Label)
Adults and Adolescents (ge 12 years) Generally Eligible for standard use.
Children (4–11 years) Eligible only under the guidance of a physician.
Children (Under 4 years) Generally Contraindicated or Not Recommended.
Pregnancy Not Recommended, especially in the first trimester; use only if physician-advised.
Lactation (Breastfeeding) Permitted, as the active substance is not significantly excreted into milk.

Use is also restricted in patients with severe abdominal pain accompanied by nausea and vomiting, and the suppository form is contraindicated in patients with anal fissures or ulcerative proctitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Stadalax (Bisacodyl) interactions is primarily focused on two areas: preventing premature tablet dissolution and mitigating additive electrolyte risk.

Administration Timing and Formulation Integrity

Co-administration of the oral enteric-coated tablet formulation with certain substances is restricted due to the risk of prematurely dissolving the protective coating. This premature dissolution can lead to gastric irritation and reduced effectiveness. Milk or milk-containing products and antacids are explicitly identified in regulatory documents as requiring separation from the Bisacodyl tablet.

  • Mandatory Separation: The enteric-coated tablets must not be taken within one hour of administering antacids or ingesting milk or milk-containing products.

Pharmacodynamic Risk of Electrolyte Imbalance

The second documented interaction domain involves the additive effect on fluid and electrolyte balance. The use of Bisacodyl with certain medicinal products may increase the risk of hypokalemia (low potassium levels) if Bisacodyl is taken in excessive doses.

  • Increased Hypokalemia Risk: Concomitant use with diuretics or adrenocorticosteroids (corticosteroids) may increase the risk of electrolyte imbalance.
  • Cardiac Glycoside Sensitivity: Electrolyte imbalance resulting from Bisacodyl use can, in turn, increase the patient's sensitivity to cardiac glycosides (e.g., Digoxin), a documented interaction concern.

Official labeling notes that the risk of fluid loss, where dehydration may be harmful, is a particular concern in susceptible populations, such as elderly patients or those with renal insufficiency.

Mechanism of Action

The mechanism of action for Stadalax (Bisacodyl) is strictly localized to the colon, initiated by the prerequisite conversion of the inactive prodrug into the active metabolite, BHPM. This conversion facilitates the metabolite's direct interaction with the colon wall's two primary targets: enteric neurons and epithelial cells.

BHPM's action is dual. First, it stimulates enteric neurons, increasing the frequency and strength of muscle contractions, or peristalsis, thereby increasing the speed of luminal contents movement and leading to decreased transit time. Second, it engages a secretagogue pathway in epithelial cells by increasing signaling mediators (like cAMP and PGE2). This drives the active secretion of ions and water into the lumen while simultaneously inhibiting water reabsorption by down-regulating specific water channels. These combined actions result in the physiological outcomes of increased propulsion and greater hydration of the contents.

Dosage and Administration Information

How Stadalax is Used: Administration Guidelines

Stadalax (Bisacodyl) is administered via two primary routes and is intended for short-term use only, typically not exceeding one week of continuous daily dosing. The administration method, dosing, and timing are structured by the specific formulation used.


Approved Forms and Dosing Regimens

Form and Route Standard Adult Dose (12+ Years) Typical Frequency
Oral Tablet (Enteric-coated, 5 mg) 5 mg to 15 mg per dose Single daily dose
Rectal Suppository (10 mg) 10 mg (one unit) per dose Single daily dose

Oral tablets are frequently taken at night to facilitate a bowel movement within 6 to 12 hours. The rectal suppository, conversely, acts much faster, generally producing an effect within 15 to 60 minutes.


Key Administration Constraints

To ensure proper function, the enteric-coated tablet must be swallowed whole with water and must never be chewed or crushed. Crucially, the tablet should not be taken within one hour of consuming antacids or milk. These constraints maintain the integrity of the coating until the drug reaches the colon.

Population-Specific Dosing

For children aged 6 to under 12 years, the oral dose is 5 mg (one tablet) administered as a single daily dose. Administration to children under the age of six requires guidance from a physician. Higher, physician-directed regimens are sometimes used to achieve complete colon evacuation prior to specific diagnostic procedures.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stadalax

Evidence for Occasional and Acute Constipation

Research exploring Stadalax for temporary constipation primarily uses short-term randomized controlled trials (RCTs) compared to placebo. These studies monitored objective measures of bowel function, such as spontaneous bowel movements (SBMs) and stool consistency. Research describes that trials monitored SBM and CSBM frequency and recorded measurements related to stool consistency. The primary limitation is the short follow-up durations, typically lasting only a few days to four weeks, meaning there is limited information for long-term outcomes.

Evidence for Pre-Procedure Bowel Evacuation

Stadalax was evaluated in research as an adjunct alongside a main cleansing agent (like PEG) before specific medical procedures. RCTs examined the quality of colon cleansing reported using standardized physician-rated scores. Research suggests that regimens incorporating Bisacodyl often tracked specific scores on the cleanliness scales. Comparative evidence is limited for Stadalax as a standalone preparation agent, and the results apply only to the specific combination regimens studied.

Studies on Chronic Constipation and Extended Use

For more persistent symptoms, researchers have explored Stadalax through medium-term RCTs and long-term retrospective observational cohort studies. Studies monitored outcomes related to daily functioning and patient experience, including changes in weekly SBM frequency and Quality of Life (QOL) scores. Long-term effects are not fully established by prospective, controlled research, and certainty remains low regarding sustained effects and dose stability when used continuously beyond four weeks.

Research in Special Populations

Studies have evaluated its use in children and older adults. While research exists on pediatric patients and data show patterns related to use in the older adult population, data for these groups remain insufficient compared to the evidence base for general adult use. The sample sizes were modest and evidence quality varies across these focused trials.

Evidence Gaps and Areas of Uncertainty

A key area of uncertainty is the lack of prospective, controlled evidence regarding sustained symptom changes for continuous use beyond four weeks. Furthermore, the results apply only to the populations studied, and comparative evidence against other treatments is limited in many instances. Research findings describe group patterns, not personal outcomes, and do not determine whether an individual will respond similarly.

Key Studies & References

  1. Bisacodyl Drug Information: MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Stadalax (FAQ)


Q: Is Stadalax an over-the-counter medicine or prescription only?

Stadalax, which contains Bisacodyl, is generally designated as an Over-the-Counter (OTC) medicine by regulatory bodies in the United States and other countries. It is typically intended for short-term relief of occasional constipation and is not usually classified as a prescription-only drug.


Q: What is the difference between Stadalax and similar medicines I've heard of?

Official information describes the active ingredient in Stadalax as a stimulant laxative and a contact laxative. This classification identifies its mechanism of action: it directly stimulates muscle movement and water secretion in the colon. This function sets it apart from other types of laxatives, such as osmotic or bulk-forming types, which operate differently.


Q: Does Stadalax cause dependence or addiction?

Regulatory warnings caution that continuous daily use for more than one week is not recommended. Prolonged daily use can lead to the body requiring laxatives to promote bowel function, often referred to as laxative abuse or reliance. Chronic overuse has been associated with issues like low potassium levels and muscle weakness.


Q: Will taking Stadalax affect my blood pressure?

The official adverse reaction documents list syncope (fainting) as a rare side effect. This event is often associated with a vasovagal response triggered by abdominal spasm or discomfort.


Q: Are there any studies comparing different doses of Stadalax?

Official documents outline the standard dose ranges for adults and children, such as 5 mg to 15 mg. While regulatory reviews cover various clinical studies, they do not typically include a summary of research directly comparing the effectiveness or safety profiles of the various individual doses (e.g., 5 mg versus 15 mg) against each other.


Q: What is the typical timeframe for seeing the full effect of Stadalax research evidence mentions?

The onset of action for the oral tablet is officially described as occurring within 6 to 12 hours. Research evidence primarily focuses on short-term relief, and regulatory summaries indicate that there is limited prospective data regarding sustained, long-term therapeutic effects beyond four weeks of continuous use.


Q: Are there any known issues with stopping Stadalax suddenly?

Regulatory guidance focuses on the risks associated with chronic overuse. In cases of extended, daily use, official sources note that abruptly stopping the medication may result in the return of constipation symptoms. No specific withdrawal syndrome is listed for appropriate, short-term use.


Q: Is it necessary to drink extra water when using Stadalax?

Official instructions advise taking the oral tablet with a glass of water. Regulatory warnings also caution about the risk of dehydration due to fluid loss in the intestine, especially with excessive use. Maintaining adequate hydration is often cited by health authorities as a beneficial component of managing constipation.


Q: Does Stadalax cause weight gain or weight loss?

According to official product information, Stadalax is a colon-acting laxative and is ineffective in altering the digestion or absorption of calories or essential nutrients in the small intestine. It is not intended for and has no documented effect on weight loss or weight gain.


Q: Are there any specific lifestyle changes mentioned in connection with Stadalax use?

Regulatory and patient advice provided by official public health bodies often suggests that maintaining a high-fiber diet and engaging in regular physical activity may help manage constipation. These lifestyle changes are often cited in medical literature as supportive measures for promoting regular bowel function.


Q: Does Stadalax interact with any common herbal supplements?

Authoritative sources typically state that there is not enough information to definitively confirm the safety or interaction profile of Bisacodyl when taken alongside herbal remedies or complementary medicines. Official information indicates that individuals should consult a healthcare professional regarding the use of herbal products.


Q: Can people with diabetes use Stadalax?

The inactive ingredients list for some Bisacodyl tablet formulations may include anhydrous lactose. While official labeling does not list diabetes as a contraindication, patients with conditions like diabetes or lactose intolerance may wish to check the exact components of the specific product formulation.


Q: What does the research say about Stadalax's effect on quality of life?

Clinical literature and research summaries compiled by government bodies mention that various studies have tracked patient experience outcomes. These outcomes include changes in metrics like Quality of Life (QOL) scores in participants using Bisacodyl for the relief of constipation symptoms.


Q: Is Stadalax described as non-habit forming in official labeling?

Some official Over-the-Counter (OTC) product labeling in the United States includes the statement that Bisacodyl is a non-habit forming laxative.


Q: Does Stadalax contain gluten or lactose?

The inactive ingredients list for some Bisacodyl tablet formulations on official drug labels includes anhydrous lactose. Official labeling does not typically confirm 'gluten-free' status, though it will list specific ingredients like corn starch.


Q: Can Stadalax cause changes in mood or anxiety levels?

While the most commonly listed side effects are physical (such as abdominal pain and dizziness), safety databases compiled from clinical reports have listed mental/mood changes (such as confusion) as a rare side effect. These are adverse events that may require medical attention.


Q: Does Stadalax interact with cold and flu medications?

Specific cold and flu medications are not explicitly listed in major drug interaction warnings. However, interaction data suggests a theoretical decrease in efficacy when Bisacodyl is combined with anticholinergic drugs, which are found in some multi-symptom cold and flu formulations.


Q: What are the signs that Stadalax is not right for me?

Regulatory labeling includes a specific 'Stop Use' warning, indicating the product should be discontinued if an individual experiences rectal bleeding or if they fail to have a bowel movement after use. These situations may indicate a more serious underlying condition.


Q: Is Stadalax the same as a medicine with a different name in another country?

Stadalax is a brand name for the active ingredient Bisacodyl. This ingredient is globally recognized and is marketed under many different brand names depending on the country. Official regulatory information confirms that the active chemical component remains the same.


Q: Can Stadalax affect sleep patterns?

Official guidance often suggests taking the oral tablet at night to allow for its 6-to-12-hour onset of action, which is timed to produce a bowel movement in the morning. Regulatory documents do not specifically list sleep disturbance as a common or uncommon side effect.


Q: Why do official documents mention that Stadalax might not work for everyone?

Regulatory reviews of research note that the results and effectiveness demonstrated in clinical trials apply only to the specific populations studied. Official documents highlight that individual response can vary, meaning it cannot be guaranteed that any single person will respond identically or achieve the same outcome as the average participant in a study.


Q: Does Stadalax require any special monitoring or lab tests?

Routine monitoring or lab tests are not prescribed for short-term, appropriate use. However, regulatory warnings state that chronic overdose can lead to clinically significant loss of fluids and electrolytes, such as potassium, which would necessitate lab tests for monitoring and treatment.


Q: What is the official guidance on taking Stadalax if I already take a vitamin supplement?

Official safety information notes that the chronic use of stimulant laxatives may potentially decrease the absorption of fat-soluble vitamins (Vitamins A, D, E, and K). This is attributed to the accelerated intestinal transit time caused by the medication.

How should Stadalax be stored and disposed of?

Stadalax (Bisacodyl) must be stored strictly according to regulatory guidelines to maintain its stability and ensure public safety. Tablets require storage below 25 C and must be protected from excessive humidity and moisture. Both the tablet and suppository forms must be kept in their original packaging or a tight, light-resistant container. A mandatory requirement across all regulatory documents is to Keep out of the sight and reach of children.

Product stability is tied to the expiry date; the medicine must not be used after the date printed on the package. Official disposal instructions strictly state that Stadalax must not be thrown away via wastewater or household waste. Unused or expired medication must be discarded following local regulations or returned to a pharmacy for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stadalax found in:

A-Z Index: